Search results
Showing 166 to 180 of 729 results for innovative
Find out more about NICE technology appraisals advisory committee D members
Find out more about NICE technology appraisals advisory committee D members
NICE has developed a medtech innovation briefing (MIB) on TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation .
SecurAcath for securing cerebrospinal fluid catheters (MIB107)
NICE has developed a medtech innovation briefing (MIB) on SecurAcath for securing cerebrospinal fluid catheters .
TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum (MIB134)
NICE has developed a medtech innovation briefing (MIB) on the TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum .
The NICE glossary provides brief definitions and explanations of terms used on the website. The terms describe how NICE works and how its guidance is produced.
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
NICE has developed a medtech innovation briefing (MIB) on Helge for detecting haemolysis .
NICE has developed a medtech innovation briefing (MIB) on RenalSense Clarity RMS for acute kidney injury .
Macimorelin for diagnosing growth hormone deficiency (MIB320)
NICE has developed a medtech innovation briefing (MIB) on macimorelin for diagnosing growth hormone deficiency .
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults.
NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .
NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .
Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)
Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults.
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)
Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.